Literature DB >> 12734319

2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.

Paula Wells1, Eric Aboagye, Roger N Gunn, Safiye Osman, Alan V Boddy, Gordon A Taylor, Imran Rafi, Andrew N Hughes, A Hilary Calvert, Pat M Price, David R Newell.   

Abstract

BACKGROUND: Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can compensate for depleted thymidine levels by taking up extracellular thymidine via a salvage pathway. We investigated the use of 2-[11C]thymidine positron emission tomography (PET) to measure thymidine salvage kinetics in vivo in humans.
METHODS: Five patients with advanced gastrointestinal cancer were PET scanned both before and 1 hour after oral administration of the TS inhibitor AG337 (THYMITAQ [nolatrexed]); seven control patients were scanned twice but not treated with AG337. Thymidine salvage kinetics were measured in vivo using 2-[11C]thymidine PET and spectral analysis to obtain the standardized uptake values (SUV), the area under the time-activity curve (AUC), and the fractional retention of thymidine (FRT). Changes in PET parameters between scans in the AG337-treated and control groups were compared using the Mann-Whitney U test. The relationship between AG337 exposure and AG337-induced changes in tumor FRT and in plasma deoxyuridine levels (a conventional pharmacodynamic systemic measure of TS inhibition) was examined using Spearman's regression analysis. Statistical tests were two-sided.
RESULTS: The between-scan change in FRT in patients treated with AG337 (38% increase, 95% confidence interval [CI] = 8% to 68%) was higher than that in control patients (3% increase, 95% CI = -11% to 17%) (P =.028). The level of AG337-induced increase in both 2-[11C]thymidine FRT and plasma deoxyuridine levels was statistically significantly correlated with AG337 exposure (r = 1.00, P =.01 for both).
CONCLUSIONS: AG337 administration was associated with increased tumor tracer retention that was consistent with tumor cell uptake of exogenous 2-[11C]thymidine as a result of TS inhibition. 2-[11C]Thymidine PET can be used to measure thymidine salvage kinetics directly in the tissue of interest.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734319     DOI: 10.1093/jnci/95.9.675

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  PET imaging of tumor growth: not as easy as it looks.

Authors:  Anthony F Shields
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 2.  Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Authors:  Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 3.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

4.  Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.

Authors:  Kong M Li; Laurent P Rivory; Janelle Hoskins; Rohini Sharma; Stephen J Clarke
Journal:  Br J Clin Pharmacol       Date:  2006-07-07       Impact factor: 4.335

5.  Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

Authors:  Yoshitaka Honma; Takashi Terauchi; Ukihide Tateishi; Daisuke Kano; Kengo Nagashima; Hirokazu Shoji; Satoru Iwasa; Atsuo Takashima; Ken Kato; Tetsuya Hamaguchi; Narikazu Boku; Yasuhiro Shimada; Yasuhide Yamada
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

6.  STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.

Authors:  Keke Liang; Evan R Abt; Thuc M Le; Arthur Cho; Amanda M Dann; Jing Cui; Luyi Li; Khalid Rashid; Amanda L Creech; Liu Wei; Razmik Ghukasyan; Ethan W Rosser; Nanping Wu; Giuseppe Carlucci; Johannes Czernin; Timothy R Donahue; Caius G Radu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

Review 7.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells.

Authors:  David A Plotnik; Lena J McLaughlin; Kenneth A Krohn; Jeffrey L Schwartz
Journal:  Nucl Med Biol       Date:  2012-05-05       Impact factor: 2.408

9.  Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.

Authors:  Kawai Yau; Patricia Price; Radhakrishma G Pillai; Eric Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

10.  Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.

Authors:  Virginie Frings; Astrid A M van der Veldt; Ronald Boellaard; Gerarda J M Herder; Elisa Giovannetti; Richard Honeywell; Godefridus J Peters; Erik Thunnissen; Otto S Hoekstra; Egbert F Smit
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.